About Us

Advanced AI Diagnosis for Every Hospital

Phantomics was founded with a vision to overcome cardiovascular diseases through accurate and reliable AI-driven diagnostic imaging technologies. Established in 2019 by Professor Byoung Wook Choi of the Radiology Department at Yonsei University Severance Hospital and Dr. Pan Ki Kim, an imaging physicist, Phantomics draws upon years of expertise in cardiac imaging. The name "Phantomics" combines "Phantom" and "Omics" to encapsulate the company's mission: acting as a virtual assistant that autonomously delivers essential diagnostic information to physicians.

Phantomics aspires to create a world where humanity is free from the burden of major diseases, including cardiovascular conditions, through cutting-edge AI diagnostic imaging technologies. By integrating advanced artificial intelligence with medical imaging, the company is developing next-generation solutions capable of detecting disease biomarkers and predicting prognoses. Through its AI-powered diagnostic platforms, Phantomics aims to revolutionize early detection and prevention of cardiovascular and other critical diseases, striving to enable every hospital worldwide to access state-of-the-art medical technologies.

Virtual Fellow: Faster Analysis, Easier Diagnosis

Cardiovascular disease, the leading cause of death worldwide and the second-highest in South Korea after cancer, is a condition where early detection and diagnosis are critical for prevention. While cardiac MRI and CT are essential for effective early diagnosis, the constantly moving nature of the heart presents challenges, including lengthy imaging times and the need for advanced expertise. Phantomics is dedicated to overcoming these limitations by lowering the barriers of cardiac MRI and CT through standardized AI, creating a win-win ecosystem for both medical professionals and patients.

Phantomics’ flagship solution, Myomics, is actively utilized in over 20 major general hospitals and secondary hospitals across South Korea, as well as in 19 international medical institutions. Its utility has been consistently proven in clinical settings. Myomics has received regulatory approvals from the Thai FDA, Malaysian MDA, and Taiwan FDA, as well as U.S. FDA clearance, ensuring its safety and reliability. In 2024, Phantomics became the first company in the Korean AI medical imaging industry to win the CES 2024 Innovation Award and the FIX Innovation Awards’ Grand Prize, further validating the outstanding innovation of its core technology in both domestic and global markets.